This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Johnson & Johnson denied quick win in CareFirst's US antitrust case over Stelara

( December 15, 2025, 23:31 GMT | Official Statement) -- MLex Summary: Johnson & Johnson and Janssen Biotech were denied a summary judgment against CareFirst’s claims of antitrust injury over J&J’s efforts to delay the introduction of biosimilar competition for the drug Stelara. US District Judge Jamar K. Walker concluded that a reasonable jury could find that but for J&J’s anticompetitive acquisition of certain Momenta patents and the ’307 patent, biosimilar companies would not have settled with J&J and would not have delayed market entry. Walker did agree to grant a judgment against certain aspects of CareFirst’s Walker Process fraud claim.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections